Linn Söderlund Diaz1, Andreas Hallqvist2. 1. Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. Linn.soderlund@vgregion.se. 2. Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract
PURPOSE: The optimal treatment strategy for vestibular schwannoma (VS) is not known, and different radiation techniques and fractionation regimens are currently being used. This report aimed to assess outcomes after LINAC-based radiosurgery (SRS) and hypofractionated radiotherapy (hypo-FSRT) and identify possible differences in outcomes between hypo-FSRT delivered in 3 or 5 fractions. METHODS: From 2005 to 2017, 136 patients underwent treatment with radiotherapy for VS. Thirty-seven patients received SRS (12 Gy), and 99 received hypo-FSRT. Hypo-FSRT was delivered in 3 fractions (total 18-21 Gy, n = 39) and 5 fractions (total 25 Gy, n = 60). RESULTS: The median follow-up was 57 months. Eight patients had progression requiring surgery, corresponding to an overall local control rate of 93.4%, with no significant difference between the fractionation schedules. A correlation with borderline significance (p = 0.052) was detected between cystic tumors and local failure. A tendency toward a higher incidence of local failure was observed after 2015 when SRS treatment increased and included slightly larger tumors. Hearing preservation was observed in 35% of patients and 36% of patients experienced acute side effects, but persistent facial or trigeminal nerve toxicity was rare. CONCLUSION: SRS and hypo-FSRT with 3 or 5 fractions provided a high rate of local control with no significant differences between treatment schedules. SRS is a well-documented radiation technique for VS and is the recommendation for small- to medium-sized tumors. This report demonstrates excellent long-term outcomes after hypo-FSRT; this regimen can be delivered safely and is an alternative for selected patients.
PURPOSE: The optimal treatment strategy for vestibular schwannoma (VS) is not known, and different radiation techniques and fractionation regimens are currently being used. This report aimed to assess outcomes after LINAC-based radiosurgery (SRS) and hypofractionated radiotherapy (hypo-FSRT) and identify possible differences in outcomes between hypo-FSRT delivered in 3 or 5 fractions. METHODS: From 2005 to 2017, 136 patients underwent treatment with radiotherapy for VS. Thirty-seven patients received SRS (12 Gy), and 99 received hypo-FSRT. Hypo-FSRT was delivered in 3 fractions (total 18-21 Gy, n = 39) and 5 fractions (total 25 Gy, n = 60). RESULTS: The median follow-up was 57 months. Eight patients had progression requiring surgery, corresponding to an overall local control rate of 93.4%, with no significant difference between the fractionation schedules. A correlation with borderline significance (p = 0.052) was detected between cystic tumors and local failure. A tendency toward a higher incidence of local failure was observed after 2015 when SRS treatment increased and included slightly larger tumors. Hearing preservation was observed in 35% of patients and 36% of patients experienced acute side effects, but persistent facial or trigeminal nerve toxicity was rare. CONCLUSION:SRS and hypo-FSRT with 3 or 5 fractions provided a high rate of local control with no significant differences between treatment schedules. SRS is a well-documented radiation technique for VS and is the recommendation for small- to medium-sized tumors. This report demonstrates excellent long-term outcomes after hypo-FSRT; this regimen can be delivered safely and is an alternative for selected patients.
Authors: Jonathan D Breshears; Joseph Chang; Annette M Molinaro; Penny K Sneed; Michael W McDermott; Aaron Tward; Philip V Theodosopoulos Journal: Neurosurgery Date: 2019-01-01 Impact factor: 4.654
Authors: Brendan M Fong; Patrick Pezeshkian; Daniel T Nagasawa; Antonio De Salles; Quinton Gopen; Isaac Yang Journal: J Clin Neurosci Date: 2012-06-15 Impact factor: 1.961
Authors: Josa M Frischer; Elise Gruber; Verena Schöffmann; Adolf Ertl; Romana Höftberger; Ammar Mallouhi; Stefan Wolfsberger; Christoph Arnoldner; Wilhelm Eisner; Engelbert Knosp; Klaus Kitz; Brigitte Gatterbauer Journal: J Neurosurg Date: 2018-03-02 Impact factor: 5.115
Authors: Ake Hansasuta; Clara Y H Choi; Iris C Gibbs; Scott G Soltys; Victor C K Tse; Robert E Lieberson; Melanie G Hayden; Gordon T Sakamoto; Griffith R Harsh; John R Adler; Steven D Chang Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: D W Andrews; O Suarez; H W Goldman; M B Downes; G Bednarz; B W Corn; M Werner-Wasik; J Rosenstock; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Kerstin A Kessel; Hanna Fischer; Marco M E Vogel; Markus Oechsner; Henning Bier; Bernhard Meyer; Stephanie E Combs Journal: Strahlenther Onkol Date: 2016-11-01 Impact factor: 3.621
Authors: Steven D Chang; Iris C Gibbs; Gordon T Sakamoto; Elizabeth Lee; Adetokunbo Oyelese; John R Adler Journal: Neurosurgery Date: 2005-06 Impact factor: 4.654
Authors: Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna Journal: J Neurooncol Date: 2022-01-18 Impact factor: 4.130